


Healthcare Industry News: Isolaz
News Release - May 22, 2007
First Painless Laser Treatment for Acne Introduced
Aesthera's Isolaz (Deep Pore Lazr Therapy) with Photopneumatic technology offers novel pore purification to clear widest range of acne typesPLEASANTON, Calif., May 22 (HSMN NewsFeed) -- Aesthera Corporation, the pioneer of technologically advanced PhotopneumaticTM (PPx(TM)) aesthetic systems, announced today the arrival of its newest painless laser therapy - Isolaz(TM) (Deep Pore Lazr Therapy) - into the consumer marketplace. Powered by Photopneumatic Technology, the Isolaz helps destroy acne causing bacteria with a combination of pneumatic energy (vacuum) and laser light for a dramatic pore purifying therapy that helps clears acne fast.
Aesthera's Isolaz(TM) (Deep Pore Lazr Therapy) offers the broadest indications of any laser or light-based system available on the market today and is the only system FDA cleared to treat comedonal and pustular acne. In addition, the Isolaz(TM) therapy is cleared to treat mild to moderate, inflammatory acne and acne vulgaris.
In addition to acne reduction, a recent clinical study showed that 64 percent of acne patients who had not responded to oral medications, topicals and traditional lasers in the past had shown greater than a 75 percent clearance of acne lesions after treatment with the Isolaz(TM) system (i). After four treatments, an 88 percent reduction in papular, pustular, comedonal and nodular acne was observed(ii).
"The Isolaz(TM) treatment is the new gold-standard that physicians and consumers should look to when treating acne, as it is the only technology that literally cleans the pores from the inside out," states Alon Maor, Co-Founder, President & CEO of Aesthera Corporation. "In contrast to traditional therapies, because the Isolaz system deep purifies the pores, many patients experience immediate gratification with noticeably clearer skin tone and texture as well as reduced pore size after the first treatment."
Patients that undergo Isolaz(TM) (Deep Pore Lazr Therapy) do not experience side effects commonly associated with lasers and acne treatments, such as redness, peeling or sun sensitivity. Additionally, immediate improvements are generally seen within the 24-48 hours of the first Isolaz(TM) treatment including a drying and flattening of the lesion. Finally, Isolaz treatments are fast and can be performed in around 10 minutes so you can have them done during lunch. Isolaz(TM) treatments also do not require pre- treatment and/or topical anesthetics.
Along with being cleared for acne, the Isolaz(TM) is also FDA cleared for the treatment of vascular and pigmented lesions as well as permanent hair reduction.
Isolaz(TM) acne therapy is offered on all of Aesthera's Isolaz(TM) and PPx(TM) systems. Currently there are over 1000 systems available worldwide. To learn were you can receive an Isolaz(TM) treatment or if you would like to receive more information on the Isolaz(TM) System please call 877.275.4779, email WeListen@AESTHERA.com or visit www.Isolaz.com.
About Aesthera Corporation
Aesthera (www.AESTHERA.com) develops, manufactures and markets light-based aesthetic treatment systems based on proprietary Photopneumatic(TM) (PPx(TM)) technology. Clinically proven to be pain-free and up to seven times faster than currently available light-based aesthetic systems, Aesthera's revolutionary systems combine the proven properties of therapeutic light with gentle pneumatic energy to more effectively work on dermal and epidermal skin targets. Aesthera allows physicians to provide powerfully painless aesthetic treatments in a system with very low cost-to-own and near-immediate profitability -- giving them the opportunity to provide best-in-class service.
i. Photopneumatic (PPx) Pore-Cleansing Acne Treatment: A breakthrough treatment option for Non-Responders to Acne Therapies, Ava T. Shamban, MD, Laser Institute for Dermatology and European Skin Care, Santa Monica, CA, October 2006.
ii. Multi-Center Data submitted to FDA, Aesthera Corporation, July 2006.
Source: Aesthera
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
